<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">J Korean Surg Soc</journal-id><journal-id journal-id-type="publisher-id">JKSS</journal-id><journal-title-group><journal-title>Journal of the Korean Surgical Society</journal-title></journal-title-group><issn pub-type="ppub">2233-7903</issn><issn pub-type="epub">2093-0488</issn><publisher><publisher-name>The Korean Surgical Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22066097</article-id><article-id pub-id-type="pmc">3204557</article-id><article-id pub-id-type="doi">10.4174/jkss.2011.81.1.25</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Comparative analysis of radiofrequency ablation and surgical resection for colorectal liver metastases</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Kyung Ho</given-names></name><xref ref-type="aff" rid="A1"></xref></contrib><contrib contrib-type="author"><name><surname>Yoon</surname><given-names>Yong Sik</given-names></name><xref ref-type="aff" rid="A1"></xref></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Chang Sik</given-names></name><xref ref-type="aff" rid="A1"></xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Tae Won</given-names></name><xref ref-type="aff" rid="A2">1</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Hye Jin</given-names></name><xref ref-type="aff" rid="A3">2</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Pyo Nyun</given-names></name><xref ref-type="aff" rid="A3">2</xref></contrib><contrib contrib-type="author"><name><surname>Ha</surname><given-names>Hyun Kwon</given-names></name><xref ref-type="aff" rid="A3">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Kim</surname><given-names>Jin Cheon</given-names></name><xref ref-type="aff" rid="A1"></xref></contrib></contrib-group><aff id="A1">Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.</aff><aff id="A2"><label>1</label>Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.</aff><aff id="A3"><label>2</label>Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.</aff><author-notes><corresp>Correspondence to: Jin Cheon Kim. Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Pungnap 2-dong, Songpa-gu, Seoul 138-736, Korea. Tel: +82-2-3010-3489, Fax: +82-2-474-9027, <email>jckim@amc.seoul.kr</email></corresp></author-notes><pub-date pub-type="ppub"><month>7</month><year>2011</year></pub-date><pub-date pub-type="epub"><day>11</day><month>7</month><year>2011</year></pub-date><volume>81</volume><issue>1</issue><fpage>25</fpage><lpage>34</lpage><history><date date-type="received"><day>29</day><month>10</month><year>2010</year></date><date date-type="accepted"><day>23</day><month>4</month><year>2011</year></date></history><permissions><copyright-statement>Copyright © 2011, the Korean Surgical Society</copyright-statement><copyright-year>2011</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0"><license-p>Journal of the Korean Surgical Society is an Open Access Journal. All articles are distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title><offsets xml_i="4115" xml_f="4122" txt_i="11" txt_f="18">Purpose</offsets></title><p><offsets xml_i="4133" xml_f="4293" txt_i="19" txt_f="179">To evaluate the comparative therapeutic efficacy of radiofrequency ablation (RFA) and hepatic resection for the treatment of colorectal liver metastasis (CRLM).</offsets></p></sec><sec><title><offsets xml_i="4315" xml_f="4322" txt_i="181" txt_f="188">Methods</offsets></title><p><offsets xml_i="4333" xml_f="4586" txt_i="189" txt_f="442">Between 1996 and 2008, 177 patients underwent RFA, 278 underwent hepatic resection and 27 underwent combination therapy for CRLM. Comparative analysis of clinical outcomes was performed including number of liver metastases, tumor size, and time of CRLM.</offsets></p></sec><sec><title><offsets xml_i="4608" xml_f="4615" txt_i="444" txt_f="451">Results</offsets></title><p><offsets xml_i="4626" xml_f="5185" txt_i="452" txt_f="1002">Based on multivariate analysis, overall survival (OS) correlated with the number of liver metastases and the use of combined chemotherapy (P &lt; 0.001, respectively). Disease-free survival (DFS) also correlated with the number of liver metastases (P &lt; 0.001). In the 226 patients with solitary CRLM &lt; 3 cm, OS and DFS rates did not differ between the RFA group and the resection group (P = 0.962 and P = 0.980). In the 70 patients with solitary CRLM ≥ 3 cm, DFS was significantly lower in the RFA group as compared with the resection group (P = 0.015).</offsets></p></sec><sec><title><offsets xml_i="5207" xml_f="5217" txt_i="1004" txt_f="1014">Conclusion</offsets></title><p><offsets xml_i="5228" xml_f="5568" txt_i="1015" txt_f="1355">The results indicate that RFA may be a safe alternative treatment for solitary CRLM less than 3 cm, with outcomes equivalent to those achieved with hepatic resection. A randomized controlled study comparing RFA and resection for patients with single small metastasis would help to determine the most efficient treatment modalities for CRLM.</offsets></p></sec></abstract><kwd-group><kwd>Radiofrequency ablation</kwd><kwd>Hepatectomy</kwd><kwd>Colorectal neoplasms</kwd><kwd>Liver metastasis</kwd></kwd-group></article-meta></front><body><sec><title><offsets xml_i="5767" xml_f="5779" txt_i="1364" txt_f="1376">INTRODUCTION</offsets></title><p><offsets xml_i="5790" xml_f="5916" txt_i="1377" txt_f="1503">Surgical resection is viewed as the gold standard of treatment for resectable liver metastasis from colorectal cancer (CRLM) [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="5947" xml_f="5948" txt_i="1503" txt_f="1504">1</offsets></xref><offsets xml_i="5955" xml_f="5956" txt_i="1504" txt_f="1505">,</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="5987" xml_f="5988" txt_i="1505" txt_f="1506">2</offsets></xref><offsets xml_i="5995" xml_f="6099" txt_i="1506" txt_f="1610">]. Several groups have reported 5-year survival rates in the range of 23 to 71% for surgical resection [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="6130" xml_f="6131" txt_i="1610" txt_f="1611">3</offsets></xref><offsets xml_i="6138" xml_f="6139" txt_i="1611" txt_f="1612">,</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="6170" xml_f="6171" txt_i="1612" txt_f="1613">4</offsets></xref><offsets xml_i="6178" xml_f="6453" txt_i="1613" txt_f="1888">]. However, only 10 to 20% of patients with CRLM are candidates for surgical resection; the majority are not suitable for resection because of anatomically ill-located lesions, functional insufficiency of hepatic reserves, medical comorbidities and extra-hepatic metastasis [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="6484" xml_f="6485" txt_i="1888" txt_f="1889">5</offsets></xref><offsets xml_i="6492" xml_f="6789" txt_i="1889" txt_f="2186">]. Radiofrequency ablation (RFA) is an alternative therapy for CRLM when hepatic resection cannot be performed. RFA has the advantage of being minimally invasive and is a relatively low-risk procedure for the treatment of focal liver tumors, especially in comparison with open surgical resection [</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="6820" xml_f="6821" txt_i="2186" txt_f="2187">6</offsets></xref><offsets xml_i="6828" xml_f="6968" txt_i="2187" txt_f="2327">]. On the other hand, RFA carries its own associated morbidity and mortality rates in both immediate post-procedure and over the long term [</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="6999" xml_f="7000" txt_i="2327" txt_f="2328">7</offsets></xref><offsets xml_i="7007" xml_f="7167" txt_i="2328" txt_f="2488">]. Furthermore, there are unresolved technical limitations associated with RFA, such as heat sink effects on nearby blood vessels and local tissue destruction [</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="7198" xml_f="7199" txt_i="2488" txt_f="2489">8</offsets></xref><offsets xml_i="7206" xml_f="7312" txt_i="2489" txt_f="2595">]. Local recurrence remains one of the greatest disadvantages of RFA for the treatment of hepatic tumors [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="7343" xml_f="7344" txt_i="2595" txt_f="2596">9</offsets></xref><offsets xml_i="7351" xml_f="7612" txt_i="2596" txt_f="2857">]. There are conflicting reports in the literature on the comparative efficacy of RFA and hepatic resection. Some results support a prospective clinical trial comparing RFA and resection, while other reports indicate that RFA is inferior to surgical resection [</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="7643" xml_f="7644" txt_i="2857" txt_f="2858">4</offsets></xref><offsets xml_i="7651" xml_f="7652" txt_i="2858" txt_f="2859">,</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="7684" xml_f="7686" txt_i="2859" txt_f="2861">10</offsets></xref><offsets xml_i="7693" xml_f="7694" txt_i="2861" txt_f="2862">,</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="7726" xml_f="7728" txt_i="2862" txt_f="2864">11</offsets></xref><offsets xml_i="7735" xml_f="7883" txt_i="2864" txt_f="3012">]. Although surgery is still the recommended treatment modality for patients with CRLM, the majority of these patients are not surgical candidates [</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="7915" xml_f="7917" txt_i="3012" txt_f="3014">12</offsets></xref><offsets xml_i="7924" xml_f="8353" txt_i="3014" txt_f="3443">]. There are few reports in the literature of randomized controlled trials comparing RFA and resection for CRLM, and analysis of comparative outcomes between RFA and resection has yielded somewhat inconsistent results. Thus, the exact role and long-term outcomes associated with RFA for CRLM are unclear. The purpose of the current study was to evaluate the comparative therapeutic efficacy of RFA and hepatic resection for CRLM.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="8394" xml_f="8401" txt_i="3445" txt_f="3452">METHODS</offsets></title><sec><title><offsets xml_i="8421" xml_f="8447" txt_i="3453" txt_f="3479">Eligibility and enrollment</offsets></title><p><offsets xml_i="8458" xml_f="9532" txt_i="3480" txt_f="4554">Between January 1996 and August 2008, 505 patients with CRLM underwent RFA, hepatic resection or a combination of RFA and resection at Asan Medical Center. All patients had liver metastasis with diagnoses by computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), ultrasonography or biopsy. Patients with extrahepatic metastasis were excluded when treatment of CRLM was performed. Of the 301 patients who underwent hepatic resection, 23 patients with positive resection margin were also excluded. Of the 482 patients included in the study, 177 were treated by RFA, 278 by curative surgical resection, and 27 by combination therapy. Synchronous colorectal cancer and liver metastases were identified in 258 (53.5%) patients and metachronous liver metastases were detected in 224 (46.5%) of the 482 patients. RFA was performed in cases of surgery-prohibitive comorbidities such as severe cardiovascular or pulmonary disease, difficult anatomical site for surgical resection, and more than four hepatic metastases over the entire liver [</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="9564" xml_f="9566" txt_i="4554" txt_f="4556">13</offsets></xref><offsets xml_i="9573" xml_f="9574" txt_i="4556" txt_f="4557">,</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="9606" xml_f="9608" txt_i="4557" txt_f="4559">14</offsets></xref><offsets xml_i="9615" xml_f="10412" txt_i="4559" txt_f="5356">]. A total of 44 (24.9%) of the 177 patients presented with comorbid diseases (13 cases of chronic obstructive pulmonary disease, 4 cases of chronic renal failure, 10 cases of liver cirrhosis, 2 transplantations and 15 cases of heart failure), and the position of the hepatic lesion was located in an anatomic site difficult for resection, such as the center of the liver, in 38 (21.5%) of the 177 patients. Otherwise, all patients with CRLM were initially considered for resection. All patients were recruited prospectively. The endpoints were recurrence, disease-free survival (DFS) and overall survival (OS). The study was conducted with the approval of the Institutional Review Board for Human Research (Asan Clinical Research Center, Seoul, Korea) in accordance with the Helsinki Declaration.</offsets></p></sec><sec><title><offsets xml_i="10434" xml_f="10458" txt_i="5358" txt_f="5382">Treatments and follow-up</offsets></title><p><offsets xml_i="10469" xml_f="11216" txt_i="5383" txt_f="6130">RFA was performed intraoperatively under general anesthesia or percutaneously under local anesthesia using ultrasonographic guidance to ensure that at least a 1-cm ablation margin was achieved around the tumor. Single or triple-cluster, 17 gauge (4.5 Fr), internally cooled electrodes (Valleylab, Boulder, CO, USA) were used. A single electrode with a 3-cm exposed tip was used for small tumors; a triple-cluster electrode with a 2.5-cm exposed tip for large tumors was used at the discretion of the radiologist. Radiofrequency current was emitted for 10 to 15 minutes with the generator set to deliver the maximum power in impedance control mode. Destruction of the liver metastasis was confirmed by follow-up CT and ultrasonography the next day.</offsets></p><p><offsets xml_i="11223" xml_f="11996" txt_i="6131" txt_f="6904">Synchronous hepatic resection by primary operation was performed on 214 patients (77.0%) and metachronous resection was done on 64 (23.0%) of the 278 patients in the resection group. Fourteen patients underwent lobectomy, 42 patients segmentectomy, and 222 patients subsegmentectomy. The surgical resection margin was 0.7 ± 0.8 cm (range, 0.1 to 7.0 cm). During laparotomy, intraoperative ultrasonography of the liver was routinely performed to detect metastatic tumors and to evaluate their anatomical location and resectability. In the RFA group, 164 (92.7%) of the 177 patients underwent post-treatment chemotherapy; 247 (88.8%) of the 278 patients in the resection group and all 27 patients (100%) in the combination therapy group underwent post-treatment chemotherapy.</offsets></p><p><offsets xml_i="12003" xml_f="12235" txt_i="6905" txt_f="7137">Follow-up was carried out postoperatively every 3 to 6 months. The evaluation included clinical examination, common blood chemistry, serum CEA, abdomen/chest CT, and specific procedures such as MRI, PET and bone scan when indicated.</offsets></p></sec><sec><title><offsets xml_i="12257" xml_f="12277" txt_i="7139" txt_f="7159">Statistical analysis</offsets></title><p><offsets xml_i="12288" xml_f="12560" txt_i="7160" txt_f="7432">Clinicopathologic continuous variables among the groups were compared using Student's t-test, Kruskal Wallis test or one-way analysis of variance with least significant difference multiple comparison. Categorical variables were compared by cross table analysis using the χ</offsets><sup><offsets xml_i="12565" xml_f="12566" txt_i="7432" txt_f="7433">2</offsets></sup><offsets xml_i="12572" xml_f="12997" txt_i="7433" txt_f="7858"> test or Fisher exact test and potential variables were verified by multivariate analysis using binary logistic regression. OS and DFS were compared using the Kaplan-Meier method with log-rank test, and survival factors were verified using a Cox proportional hazard regression model. The significance level was set at 5% for each analysis, and all calculations were performed using SPSS ver. 18 (SPSS Inc., Chicago, IL, USA).</offsets></p></sec></sec><sec><title><offsets xml_i="13025" xml_f="13032" txt_i="7861" txt_f="7868">RESULTS</offsets></title><sec><title><offsets xml_i="13052" xml_f="13092" txt_i="7869" txt_f="7909">Clinical characteristics of the patients</offsets></title><p><offsets xml_i="13103" xml_f="13195" txt_i="7910" txt_f="8002">The clinical characteristics of the 482 patients included in the analysis are summarized in </offsets><xref ref-type="table" rid="T1"><offsets xml_i="13227" xml_f="13234" txt_i="8002" txt_f="8009">Table 1</offsets></xref><offsets xml_i="13241" xml_f="13428" txt_i="8009" txt_f="8196"> (RFA, 177 patients; resection, 278 patients; combination therapy, 27 patients). Examples of radiologic findings indicating that RFA was recommended in the current study are presented in </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="13458" xml_f="13464" txt_i="8196" txt_f="8202">Fig. 1</offsets></xref><offsets xml_i="13471" xml_f="15021" txt_i="8202" txt_f="9746">. The RFA group had more patients with metachronous liver metastasis whereas the resection group had more patients with synchronous liver metastasis. All patients in the combination therapy group had synchronous liver metastasis. Both the RFA and resection groups had more patients with single metastasis; all patients in the combination therapy group had multiple metastases. The mean number of liver metastases was 1.6 (range, 1 to 5) in the RFA group, 1.5 (range, 1 to 6) in the resection group and 3.1 (range, 2 to 8) in the combination therapy group. The mean maximum tumor diameter was 2.1 cm (range, 0.5 to 6.2 cm) in the RFA group, 2.6 cm (range, 0.5 to 13.0 cm) in the resection group and 2.1 cm (range, 0.5 to 6.0 cm) in the combination therapy group. Unilobar metastases were observed in 148 (83.6%) of 177 patients in the RFA group, 224 (80.6%) of 278 patients in the resection group and 12 (44.4%) of 27 patients in the combination therapy group. There were no significant differences in the frequency of chemotherapy among the groups (P = 0.092). The mean hospitalization period was 4.2 days (range, 1 to 32 days) in the RFA group, 13.4 days (range, 7 to 42 days) in the resection group and 15.0 days (range, 8 to 66 days) in the combination group. There was no treatment-related mortality in each group. The morbidity rates were significantly lower in the RFA group (RFA group vs. resection group, 6.2% vs. 21.2%; P &lt; 0.001). The clinical features of patients with solitary CRLM &lt; 3 cm are in Table 2 and solitary CRLM ≥ 3 cm in </offsets><xref ref-type="table" rid="T3"><offsets xml_i="15053" xml_f="15060" txt_i="9746" txt_f="9753">Table 3</offsets></xref><offsets xml_i="15067" xml_f="15068" txt_i="9753" txt_f="9754">.</offsets></p></sec><sec><title><offsets xml_i="15090" xml_f="15124" txt_i="9756" txt_f="9790">Factors associated with OS and DFS</offsets></title><p><offsets xml_i="15135" xml_f="15292" txt_i="9791" txt_f="9948">Univariate and multivariate analysis using Cox proportional hazard analysis revealed several factors associated with OS after treatment of liver metastasis (</offsets><xref ref-type="table" rid="T4"><offsets xml_i="15324" xml_f="15331" txt_i="9948" txt_f="9955">Table 4</offsets></xref><offsets xml_i="15338" xml_f="15540" txt_i="9955" txt_f="10154">). OS correlated with age (P = 0.002), number of liver metastases (P &lt; 0.001) and use of chemotherapy (P = 0.002). Factors associated with DFS after treatment of liver metastasis were also analyzed (</offsets><xref ref-type="table" rid="T5"><offsets xml_i="15572" xml_f="15579" txt_i="10154" txt_f="10161">Table 5</offsets></xref><offsets xml_i="15586" xml_f="15703" txt_i="10161" txt_f="10275">). DFS was significantly related to type of treatment (RFA, P = 0.004) and number of liver metastases (P &lt; 0.001).</offsets></p></sec><sec><title><offsets xml_i="15725" xml_f="15787" txt_i="10277" txt_f="10339">Outcome for patients according to patterns of liver metastases</offsets></title><p><offsets xml_i="15798" xml_f="16257" txt_i="10340" txt_f="10796">Of the 482 patients, 296 (61.4%) had solitary liver metastasis. In the 226 patients with a single metastatic tumor &lt;3 cm (99 patients in the RFA group, 127 patients in the resection group), OS and DFS rates did not differ between patients who underwent RFA and resection (P = 0.96 and 0.98, respectively). Specifically, 5-year OS and DFS rates were 51.1% and 33.6%, respectively, in the RFA group and 51.2% and 31.6%, respectively, in the resection group (</offsets><xref ref-type="fig" rid="F2"><offsets xml_i="16287" xml_f="16293" txt_i="10796" txt_f="10802">Fig. 2</offsets></xref><offsets xml_i="16300" xml_f="16539" txt_i="10802" txt_f="11041">). Among the 70 patients with solitary metastatic tumor ≥3 cm (14 patients in the RFA group and 56 patients in the resection group), DFS rates were significantly lower in the RFA group (RFA group, 23.1%; resection group, 36.6%; P = 0.01) (</offsets><xref ref-type="fig" rid="F3"><offsets xml_i="16569" xml_f="16575" txt_i="11041" txt_f="11047">Fig. 3</offsets></xref><offsets xml_i="16582" xml_f="16584" txt_i="11047" txt_f="11049">).</offsets></p><p><offsets xml_i="16591" xml_f="16672" txt_i="11050" txt_f="11131">OS and DFS rates of the 186 patients with multiple liver metastases are shown in </offsets><xref ref-type="fig" rid="F4"><offsets xml_i="16702" xml_f="16708" txt_i="11131" txt_f="11137">Fig. 4</offsets></xref><offsets xml_i="16715" xml_f="17212" txt_i="11137" txt_f="11634"> (RFA, 64 patients; resection, 95 patients; combination therapy, 27 patients). There were no statistically significant differences in OS rates among the groups (P = 0.330). Five-year OS was 14.3% in the RFA group, 34.6% in the resection group, and 22.9% in the combination therapy group. However, DFS in the RFA group was significantly lower than the other groups (P = 0.037). The 5-year DFS rate was 6.4% in the RFA group, 16.2% in the resection group, and 18.4% in the combination therapy group.</offsets></p><p><offsets xml_i="17219" xml_f="17674" txt_i="11635" txt_f="12090">Of the 224 patients with metachronous liver metastases, 148 had solitary liver metastasis (RFA group, 103 patients; resection group, 45 patients). The 5-year OS rate was 47.6% in the RFA group and 56.0% in the resection group (P = 0.308). There was no statistical difference in 5-year DFS between the RFA and the resection groups (32.2% vs. 34.0%, P = 0.164). A trend in OS and DFS rates was observed, but the difference was not statistically significant.</offsets></p></sec></sec><sec><title><offsets xml_i="17702" xml_f="17712" txt_i="12093" txt_f="12103">DISCUSSION</offsets></title><p><offsets xml_i="17723" xml_f="17866" txt_i="12104" txt_f="12247">RFA produces coagulation necrosis using a high-frequency alternating current delivered through an electrode placed in the center of the tumor [</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="17897" xml_f="17898" txt_i="12247" txt_f="12248">8</offsets></xref><offsets xml_i="17905" xml_f="18274" txt_i="12248" txt_f="12617">]. RFA treatment often results in local tissue temperatures that approach or exceed 100℃, inducing parenchyma and tumor cell death. Ultimately, the local microvasculature is destroyed as a result of thrombosis. The use of RFA is generally not recommended for tumors larger than 5 to 6 cm because of technical limitations and the inability to achieve complete necrosis [</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="18306" xml_f="18308" txt_i="12617" txt_f="12619">15</offsets></xref><offsets xml_i="18315" xml_f="18435" txt_i="12619" txt_f="12739">]. The purpose of the current study was to compare RFA with hepatic resection for the treatment of CRLM. Mulier et al. [</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="18466" xml_f="18467" txt_i="12739" txt_f="12740">4</offsets></xref><offsets xml_i="18474" xml_f="19032" txt_i="12740" txt_f="13298">] recently advocated a randomized clinical trial comparing RFA and resection for resectable CRLM. At present, the use of RFA as an alternative treatment for patients with solitary CRLM smaller than 3 cm is controversial. Here, we showed that outcomes associated with RFA were not inferior to hepatic resection in the treatment of single CRLM of less than 3 cm. However, DFS rates after RFA were lower than surgical resection for single CRLM ≥3 cm. These findings suggest that RFA may have a valuable place in the treatment of solitary CRLM of less than 3 cm.</offsets></p><p><offsets xml_i="19039" xml_f="19166" txt_i="13299" txt_f="13426">RFA has been shown to be much less invasive than hepatic resection, with a lower complication rate and shorter hospital stays [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="19197" xml_f="19198" txt_i="13426" txt_f="13427">3</offsets></xref><offsets xml_i="19205" xml_f="19206" txt_i="13427" txt_f="13428">,</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="19238" xml_f="19240" txt_i="13428" txt_f="13430">16</offsets></xref><offsets xml_i="19247" xml_f="19248" txt_i="13430" txt_f="13431">-</offsets><xref ref-type="bibr" rid="B18"><offsets xml_i="19280" xml_f="19282" txt_i="13431" txt_f="13433">18</offsets></xref><offsets xml_i="19289" xml_f="19543" txt_i="13433" txt_f="13687">]. Our results were consistent with these studies. Results from a large multicenter study demonstrated that RFA is a relatively safe procedure for treating focal liver tumors, with a very low mortality rate of 0.2% and a major complication rate of 2.2% [</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="19574" xml_f="19575" txt_i="13687" txt_f="13688">6</offsets></xref><offsets xml_i="19582" xml_f="19998" txt_i="13688" txt_f="14104">]. Although RFA has been investigated as an alternative to surgery in terms of safety and feasibility, the comparative effectiveness of RFA and other treatment modalities has yet to be clearly demonstrated. RFA technology continues to improve, as does the skill and experience of physicians, both of which improve the potential of RFA as a treatment option for patients with CRLM. Results reported by Oshowo et al. [</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="20030" xml_f="20032" txt_i="14104" txt_f="14106">16</offsets></xref><offsets xml_i="20039" xml_f="20438" txt_i="14106" txt_f="14505">] demonstrated that survival after RFA and resection of solitary CRLM is comparable, suggesting that RFA is an effective alternative treatment to conventional surgery. A separate but related study reported that excellent local control can be achieved with RFA for small liver metastasis of less than 3 cm. Local recurrence rates reached 8.8% overall and 1.6% for CRLM smaller than 3 cm in diameter [</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="20470" xml_f="20472" txt_i="14505" txt_f="14507">19</offsets></xref><offsets xml_i="20479" xml_f="20839" txt_i="14507" txt_f="14867">]. In patients with solitary CRLM of less than 3 cm, reported 5-year survival rates, including overall and local recurrence free survival rates, were similar between RFA and surgical resection, providing further support for RFA as an alternative treatment in patients with solitary CRLM smaller than 3 cm who are not suitable candidates for hepatic resection [</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="20871" xml_f="20873" txt_i="14867" txt_f="14869">20</offsets></xref><offsets xml_i="20880" xml_f="21084" txt_i="14869" txt_f="15073">]. The results of the present study are consistent with these earlier studies as well as previous work by our group showing that RFA is a viable alternative treatment for solitary CRLM smaller than 3 cm [</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="21116" xml_f="21118" txt_i="15073" txt_f="15075">11</offsets></xref><offsets xml_i="21125" xml_f="21337" txt_i="15075" txt_f="15287">]. On the other hand, several studies have shown that RFA is associated with higher local recurrence and shorter time to progression, and that there is no difference in OS compared to hepatic resection for CRLM [</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="21369" xml_f="21371" txt_i="15287" txt_f="15289">10</offsets></xref><offsets xml_i="21378" xml_f="21379" txt_i="15289" txt_f="15290">,</offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="21411" xml_f="21413" txt_i="15290" txt_f="15292">21</offsets></xref><offsets xml_i="21420" xml_f="21561" txt_i="15292" txt_f="15433">]. These results are in line with the current finding that there was no statistically significant difference in OS between RFA and resection.</offsets></p><p><offsets xml_i="21568" xml_f="21829" txt_i="15434" txt_f="15695">RFA and resection were equivalent in terms of survival outcome in patients with solitary liver metastasis of less than 3 cm. Several studies support hepatic resection as the preferred treatment for CRLM, even in patients with solitary tumors of less than 3 cm [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="21860" xml_f="21861" txt_i="15695" txt_f="15696">3</offsets></xref><offsets xml_i="21868" xml_f="21869" txt_i="15696" txt_f="15697">,</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="21901" xml_f="21903" txt_i="15697" txt_f="15699">11</offsets></xref><offsets xml_i="21910" xml_f="21911" txt_i="15699" txt_f="15700">,</offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="21943" xml_f="21945" txt_i="15700" txt_f="15702">22</offsets></xref><offsets xml_i="21952" xml_f="21953" txt_i="15702" txt_f="15703">,</offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="21985" xml_f="21987" txt_i="15703" txt_f="15705">23</offsets></xref><offsets xml_i="21994" xml_f="22141" txt_i="15705" txt_f="15852">]. It has also been reported that survival following RFA for patients with unresectable tumors is only slightly superior to nonsurgical treatment [</offsets><xref ref-type="bibr" rid="B24"><offsets xml_i="22173" xml_f="22175" txt_i="15852" txt_f="15854">24</offsets></xref><offsets xml_i="22182" xml_f="22586" txt_i="15854" txt_f="16258">]. In the current study, the survival rate of the hepatic resection group was higher than the RFA group in patients with solitary CRLM ≥3 cm. For patients with solitary CRLM smaller than 3 cm, our results suggest that RFA is equivalent to hepatic resection. These findings appear to contradict the results of earlier studies, including previous work by our group looking at a smaller number of patients [</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="22618" xml_f="22620" txt_i="16258" txt_f="16260">11</offsets></xref><offsets xml_i="22627" xml_f="22769" txt_i="16260" txt_f="16402">]. However, these discrepancies may be due to improvements in the technical accuracy and performance of RFA in accordance with learning curve.</offsets></p><p><offsets xml_i="22776" xml_f="23077" txt_i="16403" txt_f="16704">The results of a prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma (HCC) were recently reported. Percutaneous local ablative therapy was as effective as surgical resection for the treatment of solitary and small HCC [</offsets><xref ref-type="bibr" rid="B25"><offsets xml_i="23109" xml_f="23111" txt_i="16704" txt_f="16706">25</offsets></xref><offsets xml_i="23118" xml_f="24076" txt_i="16706" txt_f="17664">]. CRLM is metastatic, whereas HCC is a primary malignancy. However, treatment modalities are identical in small solitary tumors. The results of the present study indicate that RFA is a viable treatment alternative in patients with small solitary CRLM with poor medical conditions or for whom surgical resection would be difficult, and support moving forward with a prospective randomized clinical trial comparing RFA and hepatic resection for solitary CRLM of less than 3 cm. In patients with multiple lesions, there were no significant differences in survival rates among the RFA, resection, and combination therapy groups. A trend towards slightly superior outcomes in the resection group was observed, but this was not statistically significant. These results are in agreement with previous reports that using RFA in addition to resection is beneficial in patients with multiple liver metastases because of the ability to extend the limits of resection [</offsets><xref ref-type="bibr" rid="B26"><offsets xml_i="24108" xml_f="24110" txt_i="17664" txt_f="17666">26</offsets></xref><offsets xml_i="24117" xml_f="24118" txt_i="17666" txt_f="17667">,</offsets><xref ref-type="bibr" rid="B27"><offsets xml_i="24150" xml_f="24152" txt_i="17667" txt_f="17669">27</offsets></xref><offsets xml_i="24159" xml_f="24161" txt_i="17669" txt_f="17671">].</offsets></p><p><offsets xml_i="24168" xml_f="24445" txt_i="17672" txt_f="17949">Multivariate analysis identified the number of liver metastases and treatment with chemotherapy as risk factors for OS and the number of liver metastases and type of treatment as risk factors for DFS. These results suggest that systemic treatment may be more important for OS [</offsets><xref ref-type="bibr" rid="B28"><offsets xml_i="24477" xml_f="24479" txt_i="17949" txt_f="17951">28</offsets></xref><offsets xml_i="24486" xml_f="25178" txt_i="17951" txt_f="18643">], and that local controls might be more important for DFS. The synchronicity of liver metastasis may also be an important factor in deciding whether to perform RFA or resection. In patients with metachronous CRLM, there is a tendency to avoid operation if possible because of invasiveness. Likewise, risk of damage to the diaphragm, adjacent stomach or colon would be factors against the use of RFA. For patients with solitary metachronous CRLM who want to avoid hepatic resection, RFA appears to be an attractive alternative. RFA technology continues to improve, and it may soon be possible to achieve precise targeting of tumors and larger ablation zones with a single electrode position [</offsets><xref ref-type="bibr" rid="B29"><offsets xml_i="25210" xml_f="25212" txt_i="18643" txt_f="18645">29</offsets></xref><offsets xml_i="25219" xml_f="25542" txt_i="18645" txt_f="18968">]. Thus, RFA has the potential to improve survival rates and reduce complications in selected patients with CRLM who are not suitable for or refuse hepatic resection because of comorbidities. The limitation of the present study was that this report was based on not a randomized controlled study, but a retrospective study.</offsets></p><p><offsets xml_i="25549" xml_f="25918" txt_i="18969" txt_f="19338">In conclusion, the present study suggests that RFA may be a safe alternative tool for the treatment of solitary CRLM less than 3 cm, with outcomes equivalent to those achieved with hepatic resection. A prospectively controlled study of RFA and resection for patients with single small metastasis would help to determine the most efficient treatment modalities for CRLM.</offsets></p></sec></body><back><fn-group><fn fn-type="conflict"><p>No potential conflict of interest relevant to this article was reported.</p></fn></fn-group><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheele</surname><given-names>J</given-names></name><name><surname>Stang</surname><given-names>R</given-names></name><name><surname>Altendorf-Hofmann</surname><given-names>A</given-names></name><name><surname>Paul</surname><given-names>M</given-names></name></person-group><article-title>Resection of colorectal liver metastases</article-title><source>World J Surg</source><year>1995</year><volume>19</volume><fpage>59</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">7740812</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>SM</given-names></name><name><surname>Adson</surname><given-names>MA</given-names></name></person-group><article-title>Surgical treatment of hepatic metastases from colorectal cancers</article-title><source>Arch Surg</source><year>1976</year><volume>111</volume><fpage>330</fpage><lpage>334</lpage><pub-id pub-id-type="pmid">1259571</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aloia</surname><given-names>TA</given-names></name><name><surname>Vauthey</surname><given-names>JN</given-names></name><name><surname>Loyer</surname><given-names>EM</given-names></name><name><surname>Ribero</surname><given-names>D</given-names></name><name><surname>Pawlik</surname><given-names>TM</given-names></name><name><surname>Wei</surname><given-names>SH</given-names></name><etal></etal></person-group><article-title>Solitary colorectal liver metastasis: resection determines outcome</article-title><source>Arch Surg</source><year>2006</year><volume>141</volume><fpage>460</fpage><lpage>466</lpage><pub-id pub-id-type="pmid">16702517</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulier</surname><given-names>S</given-names></name><name><surname>Ni</surname><given-names>Y</given-names></name><name><surname>Jamart</surname><given-names>J</given-names></name><name><surname>Michel</surname><given-names>L</given-names></name><name><surname>Marchal</surname><given-names>G</given-names></name><name><surname>Ruers</surname><given-names>T</given-names></name></person-group><article-title>Radiofrequency ablation versus resection for resectable colorectal liver metastases: time for a randomized trial?</article-title><source>Ann Surg Oncol</source><year>2008</year><volume>15</volume><fpage>144</fpage><lpage>157</lpage><pub-id pub-id-type="pmid">17906898</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feliberti</surname><given-names>EC</given-names></name><name><surname>Wagman</surname><given-names>LD</given-names></name></person-group><article-title>Radiofrequency ablation of liver metastases from colorectal carcinoma</article-title><source>Cancer Control</source><year>2006</year><volume>13</volume><fpage>48</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">16508626</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Livraghi</surname><given-names>T</given-names></name><name><surname>Solbiati</surname><given-names>L</given-names></name><name><surname>Meloni</surname><given-names>MF</given-names></name><name><surname>Gazelle</surname><given-names>GS</given-names></name><name><surname>Halpern</surname><given-names>EF</given-names></name><name><surname>Goldberg</surname><given-names>SN</given-names></name></person-group><article-title>Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study</article-title><source>Radiology</source><year>2003</year><volume>226</volume><fpage>441</fpage><lpage>451</lpage><pub-id pub-id-type="pmid">12563138</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curley</surname><given-names>SA</given-names></name><name><surname>Marra</surname><given-names>P</given-names></name><name><surname>Beaty</surname><given-names>K</given-names></name><name><surname>Ellis</surname><given-names>LM</given-names></name><name><surname>Vauthey</surname><given-names>JN</given-names></name><name><surname>Abdalla</surname><given-names>EK</given-names></name><etal></etal></person-group><article-title>Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients</article-title><source>Ann Surg</source><year>2004</year><volume>239</volume><fpage>450</fpage><lpage>458</lpage><pub-id pub-id-type="pmid">15024305</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curley</surname><given-names>SA</given-names></name><name><surname>Izzo</surname><given-names>F</given-names></name></person-group><article-title>Radiofrequency ablation of primary and metastatic hepatic malignancies</article-title><source>Int J Clin Oncol</source><year>2002</year><volume>7</volume><fpage>72</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">12018113</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulier</surname><given-names>S</given-names></name><name><surname>Ni</surname><given-names>Y</given-names></name><name><surname>Jamart</surname><given-names>J</given-names></name><name><surname>Ruers</surname><given-names>T</given-names></name><name><surname>Marchal</surname><given-names>G</given-names></name><name><surname>Michel</surname><given-names>L</given-names></name></person-group><article-title>Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors</article-title><source>Ann Surg</source><year>2005</year><volume>242</volume><fpage>158</fpage><lpage>171</lpage><pub-id pub-id-type="pmid">16041205</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reuter</surname><given-names>NP</given-names></name><name><surname>Woodall</surname><given-names>CE</given-names></name><name><surname>Scoggins</surname><given-names>CR</given-names></name><name><surname>McMasters</surname><given-names>KM</given-names></name><name><surname>Martin</surname><given-names>RC</given-names></name></person-group><article-title>Radiofrequency ablation vs. resection for hepatic colorectal metastasis: therapeutically equivalent?</article-title><source>J Gastrointest Surg</source><year>2009</year><volume>13</volume><fpage>486</fpage><lpage>491</lpage><pub-id pub-id-type="pmid">18972167</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>IJ</given-names></name><name><surname>Kim</surname><given-names>HC</given-names></name><name><surname>Yu</surname><given-names>CS</given-names></name><name><surname>Kim</surname><given-names>PN</given-names></name><name><surname>Won</surname><given-names>HJ</given-names></name><name><surname>Kim</surname><given-names>JC</given-names></name></person-group><article-title>Radiofrequency ablation for metachronous liver metastasis from colorectal cancer after curative surgery</article-title><source>Ann Surg Oncol</source><year>2008</year><volume>15</volume><fpage>227</fpage><lpage>232</lpage><pub-id pub-id-type="pmid">17882491</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higgins</surname><given-names>H</given-names></name><name><surname>Berger</surname><given-names>DL</given-names></name></person-group><article-title>RFA for liver tumors: does it really work?</article-title><source>Oncologist</source><year>2006</year><volume>11</volume><fpage>801</fpage><lpage>808</lpage><pub-id pub-id-type="pmid">16880239</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayo</surname><given-names>SC</given-names></name><name><surname>Pawlik</surname><given-names>TM</given-names></name></person-group><article-title>Current management of colorectal hepatic metastasis</article-title><source>Expert Rev Gastroenterol Hepatol</source><year>2009</year><volume>3</volume><fpage>131</fpage><lpage>144</lpage><pub-id pub-id-type="pmid">19351284</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>MD</given-names></name><name><surname>McCall</surname><given-names>JL</given-names></name></person-group><article-title>Systematic review of tumour number and outcome after radical treatment of colorectal liver metastases</article-title><source>Br J Surg</source><year>2009</year><volume>96</volume><fpage>1101</fpage><lpage>1113</lpage><pub-id pub-id-type="pmid">19787755</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buscarini</surname><given-names>E</given-names></name><name><surname>Savoia</surname><given-names>A</given-names></name><name><surname>Brambilla</surname><given-names>G</given-names></name><name><surname>Menozzi</surname><given-names>F</given-names></name><name><surname>Reduzzi</surname><given-names>L</given-names></name><name><surname>Strobel</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>Radiofrequency thermal ablation of liver tumors</article-title><source>Eur Radiol</source><year>2005</year><volume>15</volume><fpage>884</fpage><lpage>894</lpage><pub-id pub-id-type="pmid">15754165</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oshowo</surname><given-names>A</given-names></name><name><surname>Gillams</surname><given-names>A</given-names></name><name><surname>Harrison</surname><given-names>E</given-names></name><name><surname>Lees</surname><given-names>WR</given-names></name><name><surname>Taylor</surname><given-names>I</given-names></name></person-group><article-title>Comparison of resection and radiofrequency ablation for treatment of solitary colorectal liver metastases</article-title><source>Br J Surg</source><year>2003</year><volume>90</volume><fpage>1240</fpage><lpage>1243</lpage><pub-id pub-id-type="pmid">14515293</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillams</surname><given-names>AR</given-names></name><name><surname>Lees</surname><given-names>WR</given-names></name></person-group><article-title>Radiofrequency ablation of colorectal liver metastases</article-title><source>Abdom Imaging</source><year>2005</year><volume>30</volume><fpage>419</fpage><lpage>426</lpage><pub-id pub-id-type="pmid">15759208</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pawlik</surname><given-names>TM</given-names></name><name><surname>Izzo</surname><given-names>F</given-names></name><name><surname>Cohen</surname><given-names>DS</given-names></name><name><surname>Morris</surname><given-names>JS</given-names></name><name><surname>Curley</surname><given-names>SA</given-names></name></person-group><article-title>Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients</article-title><source>Ann Surg Oncol</source><year>2003</year><volume>10</volume><fpage>1059</fpage><lpage>1069</lpage><pub-id pub-id-type="pmid">14597445</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abitabile</surname><given-names>P</given-names></name><name><surname>Hartl</surname><given-names>U</given-names></name><name><surname>Lange</surname><given-names>J</given-names></name><name><surname>Maurer</surname><given-names>CA</given-names></name></person-group><article-title>Radiofrequency ablation permits an effective treatment for colorectal liver metastasis</article-title><source>Eur J Surg Oncol</source><year>2007</year><volume>33</volume><fpage>67</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">17174059</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hur</surname><given-names>H</given-names></name><name><surname>Ko</surname><given-names>YT</given-names></name><name><surname>Min</surname><given-names>BS</given-names></name><name><surname>Kim</surname><given-names>KS</given-names></name><name><surname>Choi</surname><given-names>JS</given-names></name><name><surname>Sohn</surname><given-names>SK</given-names></name><etal></etal></person-group><article-title>Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases</article-title><source>Am J Surg</source><year>2009</year><volume>197</volume><fpage>728</fpage><lpage>736</lpage><pub-id pub-id-type="pmid">18789428</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otto</surname><given-names>G</given-names></name><name><surname>Düber</surname><given-names>C</given-names></name><name><surname>Hoppe-Lotichius</surname><given-names>M</given-names></name><name><surname>König</surname><given-names>J</given-names></name><name><surname>Heise</surname><given-names>M</given-names></name><name><surname>Pitton</surname><given-names>MB</given-names></name></person-group><article-title>Radiofrequency ablation as first-line treatment in patients with early colorectal liver metastases amenable to surgery</article-title><source>Ann Surg</source><year>2010</year><volume>251</volume><fpage>796</fpage><lpage>803</lpage><pub-id pub-id-type="pmid">19858704</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sutherland</surname><given-names>LM</given-names></name><name><surname>Williams</surname><given-names>JA</given-names></name><name><surname>Padbury</surname><given-names>RT</given-names></name><name><surname>Gotley</surname><given-names>DC</given-names></name><name><surname>Stokes</surname><given-names>B</given-names></name><name><surname>Maddern</surname><given-names>GJ</given-names></name></person-group><article-title>Radiofrequency ablation of liver tumors: a systematic review</article-title><source>Arch Surg</source><year>2006</year><volume>141</volume><fpage>181</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">16490897</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKay</surname><given-names>A</given-names></name><name><surname>Dixon</surname><given-names>E</given-names></name><name><surname>Taylor</surname><given-names>M</given-names></name></person-group><article-title>Current role of radiofrequency ablation for the treatment of colorectal liver metastases</article-title><source>Br J Surg</source><year>2006</year><volume>93</volume><fpage>1192</fpage><lpage>1201</lpage><pub-id pub-id-type="pmid">16983740</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdalla</surname><given-names>EK</given-names></name><name><surname>Vauthey</surname><given-names>JN</given-names></name><name><surname>Ellis</surname><given-names>LM</given-names></name><name><surname>Ellis</surname><given-names>V</given-names></name><name><surname>Pollock</surname><given-names>R</given-names></name><name><surname>Broglio</surname><given-names>KR</given-names></name><etal></etal></person-group><article-title>Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases</article-title><source>Ann Surg</source><year>2004</year><volume>239</volume><fpage>818</fpage><lpage>825</lpage><pub-id pub-id-type="pmid">15166961</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>MS</given-names></name><name><surname>Li</surname><given-names>JQ</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>RP</given-names></name><name><surname>Liang</surname><given-names>HH</given-names></name><name><surname>Zhang</surname><given-names>YQ</given-names></name><etal></etal></person-group><article-title>A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma</article-title><source>Ann Surg</source><year>2006</year><volume>243</volume><fpage>321</fpage><lpage>328</lpage><pub-id pub-id-type="pmid">16495695</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shibata</surname><given-names>T</given-names></name><name><surname>Niinobu</surname><given-names>T</given-names></name><name><surname>Ogata</surname><given-names>N</given-names></name><name><surname>Takami</surname><given-names>M</given-names></name></person-group><article-title>Microwave coagulation therapy for multiple hepatic metastases from colorectal carcinoma</article-title><source>Cancer</source><year>2000</year><volume>89</volume><fpage>276</fpage><lpage>284</lpage><pub-id pub-id-type="pmid">10918156</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evrard</surname><given-names>S</given-names></name><name><surname>Becouarn</surname><given-names>Y</given-names></name><name><surname>Fonck</surname><given-names>M</given-names></name><name><surname>Brunet</surname><given-names>R</given-names></name><name><surname>Mathoulin-Pelissier</surname><given-names>S</given-names></name><name><surname>Picot</surname><given-names>V</given-names></name></person-group><article-title>Surgical treatment of liver metastases by radiofrequency ablation, resection, or in combination</article-title><source>Eur J Surg Oncol</source><year>2004</year><volume>30</volume><fpage>399</fpage><lpage>406</lpage><pub-id pub-id-type="pmid">15063893</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adam</surname><given-names>R</given-names></name><name><surname>Delvart</surname><given-names>V</given-names></name><name><surname>Pascal</surname><given-names>G</given-names></name><name><surname>Valeanu</surname><given-names>A</given-names></name><name><surname>Castaing</surname><given-names>D</given-names></name><name><surname>Azoulay</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival</article-title><source>Ann Surg</source><year>2004</year><volume>240</volume><fpage>644</fpage><lpage>657</lpage><pub-id pub-id-type="pmid">15383792</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanabe</surname><given-names>KK</given-names></name><name><surname>Kulu</surname><given-names>Y</given-names></name></person-group><article-title>Radiofrequency ablation for colon and rectal carcinoma liver metastases: what's missing?</article-title><source>Gastrointest Cancer Res</source><year>2007</year><volume>1</volume><issue>4 Suppl 2</issue><fpage>S42</fpage><lpage>S46</lpage><pub-id pub-id-type="pmid">19360147</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Fig. 1</label><caption><p>Examples of radiologic images indicating that radiofrequency ablation (RFA) was recommended in the current study. (A) Anatomic sites difficult for resection (left image, pre-RFA; right image, post-RFA). (B) Multiple lesions treated with combination therapy (left images, pre-treatment; right images, post-treatment).</p></caption><graphic xlink:href="jkss-81-25-g001"></graphic></fig><fig id="F2" position="float"><label>Fig. 2</label><caption><p>Survival of patients with solitary colorectal liver metastasis less than 3 cm treated by radiofrequency ablation (RFA) and resection. (A) Overall survival (P = 0.962). (B) Disease-free survival (P = 0.980).</p></caption><graphic xlink:href="jkss-81-25-g002"></graphic></fig><fig id="F3" position="float"><label>Fig. 3</label><caption><p>Survival of patients with solitary colorectal liver metastasis equal to or greater than 3 cm treated by radiofrequency ablation (RFA) and resection. (A) Overall survival (P = 0.152). (B) Disease-free survival (P = 0.015).</p></caption><graphic xlink:href="jkss-81-25-g003"></graphic></fig><fig id="F4" position="float"><label>Fig. 4</label><caption><p>Survival of patients with multiple colorectal liver metastasis treated by radiofrequency ablation (RFA), resection and combination therapy. (A) Overall survival (P = 0.330). (B) Disease-free survival (P = 0.037).</p></caption><graphic xlink:href="jkss-81-25-g004"></graphic></fig><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Patient clinicopathological characteristics</p></caption><graphic xlink:href="jkss-81-25-i001"></graphic><table-wrap-foot><fn><p>Values are presented as mean ± SD or number (%).</p><p>RFA, radiofrequency ablation.</p><p><sup>a)</sup>RFA vs. resection. <sup>b)</sup>RFA vs. resection vs. resection + RFA.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Clinicopathological features of patient with solitary CRLM less than 3 cm</p></caption><graphic xlink:href="jkss-81-25-i002"></graphic><table-wrap-foot><fn><p>Values are presented as mean ± SD or number (%).</p><p>CRLM, colorectal liver metastasis; RFA, radiofrequency ablation.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Clinicopathological features of patient with solitary CRLM equal to or greater than 3 cm</p></caption><graphic xlink:href="jkss-81-25-i003"></graphic><table-wrap-foot><fn><p>Values are presented as mean ± SD or number (%).</p><p>CRLM, colorectal liver metastasis; RFA, radiofrequency ablation.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Cox proportional hazard regression analysis of factors associated with overall survival after treatment of liver metastasis</p></caption><graphic xlink:href="jkss-81-25-i004"></graphic><table-wrap-foot><fn><p>Mean follow-up period: 41.2 months (range, 2.5 to 151.6 months).</p><p>CI, confidence interval; RFA, radiofrequency ablation.</p><p><sup>a)</sup>Variable selection: backward elimination.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T5" position="float"><label>Table 5</label><caption><p>Cox proportional hazard regression analysis of factors associated with disease-free survival after treatment of liver metastasis</p></caption><graphic xlink:href="jkss-81-25-i005"></graphic><table-wrap-foot><fn><p>Mean follow-up period: 21.6 months (range, 0.1 to 151.6 months).</p><p>CI, confidence interval; RFA, radiofrequency ablation.</p><p><sup>a)</sup>Variable selection: backward elimination.</p></fn></table-wrap-foot></table-wrap></floats-group></article>